FDA Third Class Thoughts Expected In Months; Agency Wants Industry Input
This article was originally published in The Tan Sheet
Executive Summary
FDA will include industry in the process of developing distribution channels between traditional Rx and OTC spaces, agency representatives told attendees of Consumer Healthcare Products Association's Regulatory and Scientific Conference
You may also be interested in...
FDA Will Accept Behind-The-Counter NDAs While Mulling “Continuum” Class
FDA is open to behind-the-counter switch applications in which companies propose innovative methods to solve access or selection issues, according to Office of Nonprescription Products staff
FDA Will Accept Behind-The-Counter NDAs While Mulling “Continuum” Class
FDA is open to behind-the-counter switch applications in which companies propose innovative methods to solve access or selection issues, according to Office of Nonprescription Products staff
FDA Will Accept Behind-The-Counter NDAs While Mulling “Continuum” Class
FDA is open to behind-the-counter switch applications in which companies propose innovative methods to solve access or selection issues, according to Office of Nonprescription Products staff